Upcoming events – Biomarin’s achondroplasia hope and Apellis’s clash with Alexion
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Alexion pays Achillion a $930m complement
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Achillion’s first oral Soliris rival hits the buffers
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Ra joins the challenge to Alexion’s Soliris stranglehold
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Upcoming events – Achillion fishes for complements as Aquestive tackles ALS
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.